E-mail Updates- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–12 of 83
Health Impact of Juvenile Idiopathic Arthritis
Characteristics of JIA
Treatment of JIA (1 of 2)
Treatment of JIA (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic
DMARDs for Treating JIA (1 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
DMARDs for Treating JIA (2 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
DMARDs Included in the Comparative Effectiveness Review
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a | azathioprine | D-penicillamine | hydroxychloroquine | leflunomide | methotrexate | sulfasalazine | adalimumab | etanercept | infliximab | abatacept | anakinra | rituximab | tocilizumab | intravenous immunoglobulin | IVIG
Clinical Questions Addressed by the CER (1 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
Clinical Questions Addressed by the CER (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | assessment instrument | reliability | validity | responsiveness
Clinically Significant Outcomes of Interest (1 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | physician global assessment | ACR Ped | parent global assessment | active joint count | erythrocyte sedimentation rate | ESR | radiographic
Clinically Significant Outcomes of Interest (2 of 2)
Adverse Effects
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic
Your slide tray is being processed.
